Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors 
in Non-small Cell Lung Cancer

Chunlu SHU, Daxing ZHU, Qinghua ZHOU

Abstract


Surgery is the standard treatment for resectable non-small cell lung cancer (NSCLC). Neoadjuvant and adjuvant therapy have been widely used for preventing recurrence and metastasis. Immune checkpoint inhibitors (ICIs) have brought long-term survival benefits in advanced NSCLC and showed higher downstage rates and pathological remission in the neoadjuvant setting. Predictive biomarkers are of great significance to identify the beneficiaries of neoadjuvant ICIs. At present, the biomarkers are still inconclusive. We summarized the clinical trials of neoadjuvant immune checkpoint inhibitors that have been disclosed so far, and reviewed the progress of the biomarkers associated with those trials.


DOI: 10.3779/j.issn.1009-3419.2022.102.04

Keywords


Lung neoplasms; Immune checkpoint inhibitor; Neoadjuvant therapy; Biomarkers

Full Text: PDF HTML

0 Citation
Alert me when cited by CSCD.
 

Bookmark and Share


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.